# Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Source: https://onco.cc/trials/nct06075264/  
OnCo record `nct06075264` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Artesunate ointment in vulvar cancer, run by Frantz Viral Therapeutics, LLC, now recruiting.

## Summary

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3) is a phase 2 interventional study registered as NCT06075264 by Frantz Viral Therapeutics, LLC, with 27 participants planned, started 2023-12-06 and due to reach its primary completion in 2026-12. Interventions recorded: Artesunate ointment and Placebo ointment.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06075264
- Phase: 2
- Setting: A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)
- Sponsor: Frantz Viral Therapeutics, LLC
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT06075264: https://clinicaltrials.gov/study/NCT06075264

## Connected records

- cancers: [Vulvar cancer](https://onco.cc/cancers/vulvar/)

---
JSON: https://onco.cc/api/v1/entities/nct06075264.json